Drug companies have made extensive efforts to develop drugs targeting the RORγ orthosteric binding site for treating autoimmune diseases and cancers but numerous challenges have arisen in cell-based assays, animal experiments and clinical trials. This evidence concerns the gene RORC and cancer.